埃索美拉唑、莫沙必利联合铝碳酸镁治疗反流性食管炎的疗效分析

Efficacy analysis of esomeprazole and mosapride accompanied by hydrotalcite on reflux esophagitis

目的探讨埃索美拉唑、莫沙必利联合铝碳酸镁(商品名:达喜)治疗反流性食管炎的临床疗效。方法将92例反流性食管炎患者随机分为治疗组和对照组(各46例),治疗组给予埃索美拉唑、莫沙必利联合铝碳酸镁治疗,对照组给予奥美拉唑联合莫沙必利治疗。结果治疗组疗效总有效率为95.7%,明显优于对照组的76.1%,两组比较差异具有统计学意义(P<0.05)。结论应用埃索美拉唑、莫沙必利联合铝碳酸镁治疗反流性食管炎疗效显著,能够明显改善患者的临床症状,具有服用方便、起效快、安全性高等优点,且不良反应少,值得临床推广。

Objective To probe into the clinical efficacy of esomeprazole and mosapride accompanied by Hydrotalcite （Talcid） on reflux esophagitis. Methods Ninety two reflux esophagitis patients were randomly divided into treatment group and control group （46 cases for each group）. Esomeprazole and mosapride accompanied by hydrotalcite were administrated to treatment group; and omeprazole accompanied by mosapride were given to control group, Results The total effective rate of treatment group was 95.7%, which was obviously better than that of control group 76,1%, the difference between them had statistical significance （P 〈 0.05）. Conclusion The clinical efficacy of esomeprazole and mosapride accompanied by hydrotalcite on reflux esophagitis is very outstanding, It can improve the clinical symptoms of patients. And it has more advantages with less untoward effects, For example, it is easy to be taken with rapid onset and high safety. Therefore, it is worthy of clinical popularization.